Lowest price guarantee and savings with every new order!



On all orders over £240

Harvoni (Sofosbuvir - Ledipasvir)

General Info Hide Show


Harvoni is an antiretroviral medicine indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection and HCV/HIV-1 co-infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg without or with compensated or decompensated cirrhosis or those who had a liver transplantation.

UK Mail, Reg.Mail Royal Mail, EMS

Approximate Delivery Date:
August, 08 - August, 19
Approximate Delivery Date:
July, 26 - August, 01

In Stock

Harvoni 400mg + 90mg; 28 pills bottle

1 bottle
£629.05 per bottle
£629.05 £786.31 per bottle

Latest Harvoni Reviews:

General Info

Harvoni is an antiretroviral medicine indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection and HCV/HIV-1 co-infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg without or with compensated or decompensated cirrhosis or those who had a liver transplantation.

Active Ingredient

Sofosbuvir, Ledipasvir.


Harvoni is a combination medicine used for the treatment of a long-term infection of the liver induced by the hepatitis C virus. The medication treats genotype 1 of hepatitis C virus infection in people whose liver is scarred but still able to perform its basic functions at some level - compensated cirrhosis or those whose liver is extensively damaged and scarred and unable to function in a proper way - decompensated cirrhosis. It is also suitable for administration in patients who have undergone a liver transplantation. The medicine is also utilized for the treatment of patients who have both human immunodeficiency virus (HIV-1) and hepatitis C virus infections.

The drug is comprised of the two direct-acting antiviral agents against the hepatitis C virus (HCV): Sofosbuvir and Ledipasvir. The first one, Sofosbuvir, is a representative of a nucleotide analog drug family which acts as an HCV NS5B nucleotide polymerase inhibitor, preventing the virus from copying itself. Ledipasvir is an NS5A complex inhibitor which works by suppressing the activity of the protein required for the viral multiplication. These active ingredients in combination have a synergistic effect on the hepatitis C virus as they suppress its replication and spread through the body, thereby improving hepatic function and keeping off the disease complications, and even liver cancer development. Ledipasvir and Sofosbuvir may also be given in combination with another antiretroviral agent called Ribavirin.

Harvoni cannot completely kill either HCV or HIV, hence, patients should be cautious to avoid the virus transmission to the others. The virus may be spread through exposing yourself to contaminated blood (e.g., needle/razor sharing) or practicing ‘unsafe’ sex (i.e., without contraceptive measures).


Concomitant therapy of chronic hepatitis C virus genotype 1 (HCV) infection in patients:

  • with or without compensated/decompensated cirrhosis (including post-transplant);
  • with HCV/HIV-1 co-infection.
MOA (mechanism of action)

Sofosbuvir is the first‐in‐class NS5B RNA-dependent polymerase inhibitor. Once this active ingredient is administered, Sofosbuvir metabolizes to its active form - nucleoside analog triphosphate (GS-461203). It is then incorporated into the RNA by the NS5B polymerase where it suppresses HCV replication and terminates viral chain elongation. Ledipasvir, in its turn, targets NS5A protein, which is essential for the virus reproduction, assembly, and secretion, thus, not allowing the hepatitis C virus (HCV) to multiply and infect other healthy cells in the body.


Before initiating the treatment with Harvoni, all patients should undergo special blood tests to check for the evidence of active or prior hepatitis B virus (HBV) infection. The combination of Ledipasvir and Sofosbuvir comes as a tablet to take by mouth. The medicine should be administered once a day without regard to food. Swallow the tablets whole without chewing, crushing or splitting them.

The maximum daily dosage should not exceed 400/90 mg (400 mg of Sofosbuvir and 90 mg of Ledipasvir). The course of treatment with Harvoni varies depending on the patient’s conditions and his/her response to the drug administration and is usually 12 to 24 weeks long. One should continue taking Ledipasvir and Sofosbuvir tablets for as long as recommended by a doctor and not to stop the therapy because it may cause severe hepatitis C virus outbreak.

Missing a dose

If you miss a dose of Harvoni you should take it as soon as you remember. If it is the time for the next dose you should continue your regular dosing schedule. Do not take a double dose to make up for a missed one.


If an overdose occurs and you are feeling unwell, you should seek emergency medical attention or contact your healthcare provider immediately.


Store at room temperature under 30°C (86°F) away from excess moisture and heat. Do not use Harvoni if the seal is missing or broken. Keep the bottle tightly closed. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Safety Information

Side effects

The most common side effects associated with Harvoni are:

  • tiredness
  • headache
  • nausea
  • diarrhea
  • difficulty sleeping
  • slow or irregular heartbeat
  • cough
  • shortness of breath
  • dizziness
  • irritability
  • rash
  • swelling of the face, lips, tongue or throat
  • muscle pain

Side effect occurrence does not only depend on medication you are taking but also on your overall health and other factors.


Do not take Harvoni if you are allergic to the components it is comprised of - Sofosbuvir and Ledipasvir.

Do not use the drug if you have serious problems with your kidneys or you are on dialysis.

Do not take the medicine if you have hepatitis B virus (HBV) infection and are not receiving HBV antiviral therapy as the treatment of hepatitis C virus infection may reactivate HBV multiplication. Do not use the tablets if you are going to have a liver transplantation.

Do not administer the medication concomitantly with other medicinal products containing Sofosbuvir and/or Ledipasvir.

Do not use Harvoni concomitantly with P-gp inducers (e.g., rifampin, St. John’s Wort), acid-reducing agents, antibiotic used to treat infections, including tuberculosis (like rifapentine), medications for the treatment of epilepsy and prevention of seizures (such as oxcarbazepine), anti-HIV infection drugs (tipranavir, tenofovir disoproxil), some other medicines used to treat hepatitis C virus infection (like simeprevir), agents for the treatment of irregular heartbeat (amiodarone) or other heart conditions (digoxin), medications used to thin the blood (dabigatran) and statins to treat high cholesterol.

Consult your doctor before taking any medicines for the treatment of stomach ulcers, heartburn or acid reflux as their administration may require changes due to Harvoni concomitant intake.

Do not take the medication if you are pregnant or breastfeeding without consulting your doctor.

Do not give the drug to patients younger than 12 years of age weighing less 35 kg without a doctor’s advice.

Delivery Information
Destination Service Tracking Delivery Time Price
Worldwide Not trackable 14-21 working days £12.00 per order
Trackable, where available 5-9 working days £20.00 per order

Your order will be packed safely and dispatched within 24 hours.


This is how exactly your parcel looks like. It is similar to a regular private letter, which does not disclose its contents. Size: 9.4x4.3x0.3 inches (24x11x0.7cm).


Soft Discount Pack

Erectile Problems? Soft Discount Pack x 180 pills Viagra Soft free

£98.00 £204.16 Shop Now
52% OFF
Do not show "Last Viewed"

Last Viewed



Harvoni is an antiretroviral medicine indicated for the treatment of chronic hepatiti...

£629.05 per bottle £786.31
Trust Pilot RPS CQC Sage-Pay Norton

Discount Coupon